Literature DB >> 16387989

Depression and stages of Huntington's disease.

Jane S Paulsen1, Carissa Nehl, Karin Ferneyhough Hoth, Jason E Kanz, Michelle Benjamin, Rachel Conybeare, Bradley McDowell, Beth Turner.   

Abstract

Individuals with manifest Huntington's disease (HD) were interviewed with regard to the presence, frequency, and severity of depression symptoms to better characterize depressed mood across the disease course in HD. Rates of depression were more than twice that found in the general population. One-half reported that they had sought treatment for depression, and more than 10% reported having at least one suicide attempt. The proportion of HD patients endorsing significant depression diminished with disease progression. Despite the public health impact of depression, available treatments are underutilized in HD, and research is needed to document the efficacy and effectiveness of standard depression treatments in this population.

Entities:  

Mesh:

Year:  2005        PMID: 16387989     DOI: 10.1176/jnp.17.4.496

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  62 in total

1.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness.

Authors:  Kevin Duff; Jane S Paulsen; Leigh J Beglinger; Douglas R Langbehn; Chiachi Wang; Julie C Stout; Christopher A Ross; Elizabeth Aylward; Noelle E Carlozzi; Sarah Queller
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2010       Impact factor: 2.198

3.  Challenges assessing clinical endpoints in early Huntington disease.

Authors:  Jane S Paulsen; Chiachi Wang; Kevin Duff; Roger Barker; Martha Nance; Leigh Beglinger; David Moser; Janet K Williams; Sheila Simpson; Douglas Langbehn; Daniel P van Kammen
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

4.  Increased irritability, anxiety, and immune reactivity in transgenic Huntington's disease monkeys.

Authors:  Jessica Raper; Steven Bosinger; Zachary Johnson; Gregory Tharp; Sean P Moran; Anthony W S Chan
Journal:  Brain Behav Immun       Date:  2016-07-07       Impact factor: 7.217

Review 5.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

Review 6.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

7.  Three-dimensional surface mapping of the caudate nucleus in late-life depression.

Authors:  Meryl A Butters; Howard J Aizenstein; Kiralee M Hayashi; Carolyn C Meltzer; Jamie Seaman; Charles F Reynolds; Arthur W Toga; Paul M Thompson; James T Becker
Journal:  Am J Geriatr Psychiatry       Date:  2009-01       Impact factor: 4.105

8.  Perceived stress in prodromal Huntington disease.

Authors:  Nancy Downing; Megan M Smith; Leigh J Beglinger; James Mills; Kevin Duff; Kelly C Rowe; Eric Epping; Jane S Paulsen
Journal:  Psychol Health       Date:  2011-06-21

9.  Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise.

Authors:  Thibault Renoir; Terence Y C Pang; Michelle S Zajac; Grace Chan; Xin Du; Leah Leang; Caroline Chevarin; Laurence Lanfumey; Anthony J Hannan
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

10.  Proteomic Analysis of the Hippocampus in Mouse Models of Trigeminal Neuralgia and Inescapable Shock-Induced Depression.

Authors:  Qing-Huan Guo; Qing-He Tong; Ning Lu; Hong Cao; Liu Yang; Yu-Qiu Zhang
Journal:  Neurosci Bull       Date:  2017-04-19       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.